Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review

American Journal of Hematology

Volumn 84, Issue 10, 2009, Pages 671-677

  Pinchon, Deborah J ^a   Stanworth, Simon J ^b   Dorée, Carolyn ^b   Brunskill, Susan ^b   Norfolk, Derek R ^c  

^a HULL ROYAL INFIRMARY   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLOSPORIN; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; RETINOIC ACID; TOCOPHEROL;

ADULT; AGED; CANCER THERAPY; CONSENSUS; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; ORGANIZATION; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; REVIEW; SYSTEMATIC REVIEW;

ERYTHROCYTE TRANSFUSION; HUMANS; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE;

EID: 70349502130     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21503     Document Type: Review

References (29)

1. British Committee for Standards in Haematology. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003;120:87-200.
2. Hellström-Lindberg E, Malcovati L. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol 2008;45:14-22.
3. Lacroix J, Hébert PC, Hutchison JS, et al.; TRIPICU Investigators; Canadian Critical Care Trials Group; Pediatric acute lung injury and sepsis investigators network. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med 2007;356:1609-1619.
4. Bowling A. Measuring Disease, 2nd ed. Buckingham and Philadelphia: Oxford University Press; 2001.
5. Kornblith AB, Herndon JE II, Silverman L, et al. Impact of azacytadine on quality of life of patients with myelodyplastic syndrome in a randomised phase III trial: A cancer and leukemia group B study. J Clin Oncol 2002;20:2441-2452. (Pubitemid 34525729)
6. Atoyebi W, Bywater L, Rawlings L, et al. Treatment of myelodysplasia with oral cyclosporin. Clin Lab Haematol 2004;24:211-214.
7. Caocci G, Baccoli R, Ledda A, et al. A mathematical model for the evaluation of amplitude of haemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: Correlation with quality of life and fatigue. Leuk Res 2007;31:249-252. (Pubitemid 44872897)
8. Olivia EN, Dimitrov BD, Benedetto F, et al. Hemoglobin level threshold for cardiac remodelling and quality of life in myelodysplastic syndrome. Leuk Res 2005;29:1217-1219. (Pubitemid 41169239)
9. Stasi R, Abruzzese E, Lanzetta G, et al. Darbopoetin alfa for the treatment of anemic patients low and intermediate 1 risk myelodysplastic syndromes. Ann Oncol 2005;16:1921-1927. (Pubitemid 41724281)
10. Giagounidis AAN, Haase S, Germing U, et al. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q-33 with a combination of all-trans-retinoic acid and tocopherol-a: A phase II study. Ann Hematol 2005;84:389-394. (Pubitemid 40823353)
11. Kantarajian H, Issa JPJ, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer 2006;106:1794-1803.
12. Balleari E, Rossi E, Clavio M, et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anaemia in low-risk myelodysplastic syndromes: Results from a randomized single-centre study. Ann Hematol 2006;85:174-180. (Pubitemid 43174272)
13. Casadevall N, Durieux P, Dubois S, et al. Health economic, and quality of life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: A randomized, controlled trial. Blood 2004;104:321-327. (Pubitemid 38900010)
14. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue and cytokine levels in patients with acute myelogenous leukaemia or myelodysplastic syndrome. Cancer 2005;104:788-793. (Pubitemid 41113679)
15. Gabrilove J, Paquette R, Lyons RM, et al. Phase 2, single arm trial to evaluate the effectiveness of darbopoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008;142:379-393. (Pubitemid 351962168)
16. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anemia of myelodysplastic syndromes with erythropoietin + granulocyte-colony stimulating factor: Significant effects on quality of life. Br J Haematol 2003;120:1037-1046. (Pubitemid 36411563)
17. Spiriti MAA, Latagliata R, Niscola P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 2005;84:167-176. (Pubitemid 40260326)
18. Clavio M, Nobili F, Balleari E, et al. Quality of life and brain function following high dose recombinant human erythropoietin in low risk myelodysplastic syndromes: A preliminary report. Eur J Haematol 2004;72:113-120. (Pubitemid 38161159)
19. Steensma DP, Heptinstall KV, Johnson VM, et al. Common troublesome symptoms and their impact upon quality of life in patients with myelodysplastic syndrome (MDS): Results of a large internet based survey. Leuk Res 2008;32:691-698.
20. Heptinstall K. Quality of life in myelodysplastic syndromes: A special report from the myelodysplastic syndromes foundation inc. Oncol Nurs Ed 2008;22:13-18.
21. Jansen AJG, Essink-Bot ML, Beckers EAM, et al. Quality of life measurement in patients with transfusion-dependant myelodysplastic syndromes. Br J Haematol 2003;121:270-274. (Pubitemid 36560593)
22. Olivia EN, D'Angelo A, Martino B, et al. More concern about transfusion requirement when evaluating quality of life in anemic patients. J Clin Oncol 2002;20:3182-3183. (Pubitemid 34791112)
23. Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in cancer clinical trials: Serious problems and challenges. Stat Med 1998;17:517-532.
24. Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: Properties, applications and interpretation. Health Qual Life Outcomes 2003;1:79. (Pubitemid 39111917)
25. Cella D. The functional assessment cancer therapy-anaemia (FACT-An) scale: A new instrument for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34:13-19. (Pubitemid 27319140)
26. Aaronson NK, Ahmedzai S, Bergman B, et al. The European organisation for research and treatment of cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1999;85;365-376.
27. Garratt A. Patient reported outcome measures in trials. Br Med J 2009; 338a:2597.
28. National Institute for Health and Clinical Excellence. Epoetin Alfa, Epoetin Beta and Darbepoetin Alfa for Cancer Treatment Induced Anaemia. NICE Technology Appraisal Guidance 142. London: NICE; 2008.
29. Paisley S, Booth A, Mensinkai S. Chapter 12: Health-related quality of life studies. In: Topfer LA, Auston I, editors. Etext on Health Technology Assessment (HTA) Information Resources 2005. Available at: http://www.nlm.nih. gov/archive/20060905/nichsr/ehta/chapter12.html.